Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Novavax Inc (NVAX)

Novavax Inc (NVAX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,114,743
  • Shares Outstanding, K 162,499
  • Annual Sales, $ 682,160 K
  • Annual Income, $ -187,500 K
  • EBIT $ 307 M
  • EBITDA $ 356 M
  • 60-Month Beta 2.30
  • Price/Sales 1.63
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 80.50% (+12.52%)
  • Historical Volatility 45.68%
  • IV Percentile 42%
  • IV Rank 14.00%
  • IV High 251.06% on 11/05/25
  • IV Low 52.73% on 06/30/25
  • Expected Move (DTE 7) 0.58 (8.43%)
  • Put/Call Vol Ratio 0.20
  • Today's Volume 3,304
  • Volume Avg (30-Day) 7,558
  • Put/Call OI Ratio 0.63
  • Today's Open Interest 306,375
  • Open Int (30-Day) 309,077
  • Expected Range 6.28 to 7.44

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.66
  • Number of Estimates 4
  • High Estimate -0.31
  • Low Estimate -1.37
  • Prior Year -0.51
  • Growth Rate Est. (year over year) -29.41%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.20 +10.65%
on 11/20/25
7.92 -13.38%
on 11/06/25
-0.65 (-8.66%)
since 11/04/25
3-Month
6.20 +10.65%
on 11/20/25
9.75 -29.64%
on 10/03/25
-0.93 (-11.94%)
since 09/04/25
52-Week
5.01 +36.93%
on 04/10/25
11.55 -40.61%
on 01/07/25
-1.44 (-17.35%)
since 12/04/24

Most Recent Stories

More News
Novavax to Participate in Jefferies London Healthcare Conference

GAITHERSBURG, Md. , Nov. 12, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the following upcoming investor conference:

NVAX : 6.86 (+0.29%)
Novavax: Q3 Earnings Snapshot

Novavax: Q3 Earnings Snapshot

NVAX : 6.86 (+0.29%)
Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights

GAITHERSBURG, Md. , Nov. 6, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the third quarter ended September 30, 2025.

NVAX : 6.86 (+0.29%)
Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovidâ„¢, Triggering a $25 Million Milestone Payment

GAITHERSBURG, Md. , Nov. 4, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) has completed the transfer of the U.S. marketing authorization for its COVID-19 vaccine, Nuvaxovid™ to Sanofi, enabling...

NVAX : 6.86 (+0.29%)
Novavax to Report Third Quarter 2025 Financial Results on November 6, 2025

GAITHERSBURG, Md. , Oct. 30, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its third quarter 2025 financial results and operational highlights at 8:30 a.m. Eastern...

NVAX : 6.86 (+0.29%)
Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy

GAITHERSBURG, Md. , Oct. 22, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it has further executed against its planned transformation into a lean, agile operating model...

NVAX : 6.86 (+0.29%)
Novavax Transfers EU Vaccine Rights to Sanofi

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Novavax (...

NVAX : 6.86 (+0.29%)
Novavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment

GAITHERSBURG, Md. , Oct. 7, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) has completed the transfer of the marketing authorization for its COVID-19 vaccine, Nuvaxovid® to Sanofi, in the European...

NVAX : 6.86 (+0.29%)
Novavax Announces Progress on Sanofi Agreement

GAITHERSBURG, Md. , Sept. 30, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced progress on its collaboration and license agreement  (CLA) with Sanofi regarding...

NVAX : 6.86 (+0.29%)
Nuvaxovid® Now Approved in Japan Triggering Takeda Milestone Payment

GAITHERSBURG, Md. , Sept. 4, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced a milestone payment* from Takeda has been triggered by regulatory approval for Novavax's...

NVAX : 6.86 (+0.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Novavax, Inc. is a biotechnology company engaged in developing innovative vaccines to prevent serious infectious diseases. The company is also developing proprietary immune stimulating saponin-based adjuvants, namely Matrix-M, which already enhanced immune responses and were well-tolerated in multiple...

See More

Key Turning Points

3rd Resistance Point 7.05
2nd Resistance Point 6.96
1st Resistance Point 6.91
Last Price 6.86
1st Support Level 6.77
2nd Support Level 6.68
3rd Support Level 6.63

See More

52-Week High 11.55
Fibonacci 61.8% 9.05
Fibonacci 50% 8.28
Fibonacci 38.2% 7.51
Last Price 6.86
52-Week Low 5.01

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar